ClinicalTrials.gg
CompletedNCT04488900Updated Feb 15, 2024

Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects

A Phase 1 interventional study of CKD-508 Capsule and Placebo Capsule in Healthy Subjects, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-15.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is a first-in-human, randomized, placebo-controlled, 4-part, single ascending dose and multiple ascending dose study. The study is designed to assess the safety, tolerability, PK, and PD and food effect of orally administered CKD-508 capsules and tablets in healthy subjects.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject voluntarily agrees to participate in this study and signs an Independent Ethics Committee (IEC)-approved prior to performing any of the Screening Visit procedures.
  • Males and females between 18 to 55 years of age, inclusive, at the Screening Visit.
  • Females of non- (surgically sterile [hysterectomy or oophorectomy] or (amenorrhea for more than 12 months with follicle-stimulating hormone (FSH) in postmenopausal range confirmed by an FSH test).
  • Males must be unable to procreate (defined as surgically sterile [i.e., had a vasectomy ≥6 months prior to screening]) or must agree to use highly effective form of from screening through 90 days after study completion.
  • Non-smokers (or other nicotine use) as determined by history (no nicotine use over the past 6 months).

Exclusion criteria

Exclusion Criteria:

  • Subject has history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological or psychiatric disorder(s) as determined by the PI or designee.
  • Subject has any disorder that would interfere with the absorption, distribution, metabolism or excretion of drugs.
  • Subject has any concurrent disease or condition that, in the opinion of the PI, would make the subject unsuitable for participation in the clinical study.
  • Subject has history of alcohol and/or illicit drug abuse within 2 years of Screening Visit.
  • Subject has positive test for surface antigen (HBsAg), antibody or (HIV) antibody.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Part 1. CKD-508 Capsule in Single Dose

    Single dose of CKD-508 capsules

    Drug: CKD-508 Capsule

  • Placebo comparator
    Part 1. Placebo Capsule in Single Dose

    Single dose of Placebo capsules

    Drug: Placebo Capsule

  • Experimental
    Part 2. CKD-508 Tablet in Single Dose

    Single dose of CKD-508 tablets for biocompartibility

    Drug: CKD-508 Tablet

  • Placebo comparator
    Part 2. Placebo Tablet in Single Dose

    Single dose of Placebo tablets for biocompartibility

    Drug: Placebo Tablet

  • Experimental
    Part 3. CKD-508 Tablet in Single Dose

    Single dose of CKD-508 tablets for food effect

    Drug: CKD-508 Tablet

  • Placebo comparator
    Part 3. Placebo Tablet in Single Dose

    Single dose of Placebo tablets for food effect

    Drug: Placebo Tablet

  • Experimental
    Part 4. CKD-508 Tablet in Multiple Dose

    Multiple dose of CKD-508 tablets

    Drug: CKD-508 Tablet

  • Placebo comparator
    Part 4. Placebo Tablet in Multiple Dose

    Multiple dose of placebo tablets

    Drug: Placebo Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and tolerability including treatment-emergent AE and treatment-emergent SAE

    Time frame: 28 days post the final dose

Secondary outcomes

  1. Maximum plasma CKD-508 concentrations after dosing

    Peak plasma concentration (Cmax)

    Time frame: 28 days post the final dose

  2. Time of maximum plasma CKD-508 concentrations after dosing

    Time of peak plasma concentration (Tmax)

    Time frame: 28 days post the final dose

  3. Changes from baseline in plasma CKD-508 concentrations in time after dosing

    Area under the plasma concentration versus time curve (AUC)

    Time frame: 28 days post the final dose

  4. Changes from baseline in CETP activity after dosing

    Pharmacodynamics endpoint

    Time frame: 28 days post the final dose

  5. Changes from baseline in lipid parameters after dosing

    including, but not limited to the following: LDL-C, etc. Pharmacodynamics endpoint

    Time frame: 14 days post the final dose

07

Study locations

1 site
  • Northwick Park Hospital
    Harrow, Middlesex HA1 3UJ, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Jul 2023, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2020
First posted
Jul 28, 2020
StartActual
Jul 6, 2020
Primary completionActual
Jul 2, 2023
CompletionActual
Jul 2, 2023
Last update
Feb 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04488900
Responsible party
Sponsor
First posted
Jul 28, 2020
Start date
Jul 6, 2020
Primary completion
Jul 2, 2023
Completion
Jul 2, 2023
Last update
Feb 15, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CKD-508

Start the discussion